Intensive rituximab regimen in immune-mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment

Br J Haematol. 2021 Jan;192(1):e21-e25. doi: 10.1111/bjh.17170. Epub 2020 Nov 20.

Christophe Barba^{1

2}, Marion Peyre^{1

2}, Lionel Galicier^{1

3}, Pascal Cathebras⁴, Dana Ranta⁵, Sandrine Malot¹, Agnès Veyradier^{1

6}, Paul Coppo^{1

2

7}

¹ Centre de Référence des MicroAngiopathies Thrombotiques, Paris, France.
² Service d'hématologie, AP-HP. Sorbonne-Université, Paris, France.
³ Service d'Immunopathologie, Hôpital Saint-Louis, AP-HP, Paris, France.
⁴ Service de Médecine Interne, Centre Hospitalier Universitaire de St Etienne, Paris, France.
⁵ Service d'Hématologie, Centre Hospitalier Universitaire de Nancy, Paris, France.
⁶ Service d'Hématologie Biologique - Hémostase, Hôpital Lariboisière, Paris, AP-HP, France.
⁷ INSERM UMRS 1138, Paris, France.

No abstract available

Keywords: ADAMTS13; immunomodulation; intensification; ofatumumab; rituximab; thrombotic thrombocytopenic purpura.

Publication types